Introduction
Use of conjugate vaccines for the prev v vention of Haemophilus influenzae type b (Hib) disease in children has subv v stantially decreased the burden of disease in developed [1] [2] [3] and developing countries. [4] [5] [6] [7] These vaccines are highly effective against invasive disease and may prevent up to 25% of radiographiv v cally confirmed pneumonia, [8] [9] [10] but are not used in some developing countries due to their high cost and because Hib remains undervrecognized as a cause of severe disease and death. 11 The vaccinev preventable burden of Hib disease is likely to be greater among HIVvinfected than among uninfected children due to much higher rates of Hib disease. 12 The vaccines have, however, been less effective in HIVvinfected children, [13] [14] highlighting the need for evaluation of the impact of vaccine introduction in South Africa was the first country in Africa to selfvfinance and incorporate the Hib vaccine into its routine child immunization schedule from July 1999. It concurrently established a national laboratoryvbased surveillance for invasive Hib disease to document the impact of routine vaccination on Hib disease. 15 We analysed data from this surveillance system for the first five years to document changes in the number of reported cases of laboratoryvconfirmed H. influenzae disease among children less than five years old in South Africa.
Impact of conjugate Haemophilus influenzae type b (Hib) vaccine introduction in South Africa

Methods
South Africa introduced the Hib vaccine (Tetramune, Wyeth Lederle Vaccines and Pediatrics) in March 1998 as part of a pneumococcal conjugate vaccine trial in Soweto (urban black community with 120 000 children less than five years old in 1995), Gauteng province, affecting a total of 19 267 children.
14 Populationv based studies in South Africa had previv v ously demonstrated rates of invasive Hib disease of 170 per 100 000 infants below one year of age. 14, 16 National populav v tion estimates for children less than five years old in 2002 were 4 455 000, and in Gauteng and Western Cape (from where majority of the disease is reported) 737 600 and 409 600, respectively.
National laboratory-based surveillance system
The surveillance system defined inv v vasive H. influenzae and Streptococcus pneumoniae disease as isolation of the organisms from normally sterile body fluids of South Africans of all ages. 15 
Hib conjugate vaccine
The vaccine was part of a combination product (CombActHIB, Aventis Pasteur) containing diphtheria toxoid, tetanus toxoid and whole cell pertussis antigen (DTwP) for children receiving their first dose of diphtheria-tetanus-pertussis vaccine. The vaccine was prepared by reconstituting dried Hib conjugate powv v der with DTwP as diluent. The recomv v mended dosage schedule was at six, 10 and 14 weeks without booster. There was no catchvup schedule for vaccinating children who had already received their first dose of DTwP. We experienced sporadic shortages of the combination vaccine from 1999 through 2002.
Identification of isolates
We identified isolates with the gvaminov v laevulinic acid (ALA)vporphyrin test reaction and API NH (bioMérieux sa, Marcyvl'Etoile, France). 17 Slide aggluv v tination for serotyping was performed using agglutinating sera for types a-f (Murex Biotech Ltd, Dartford, Kent, England). Serotyping results for all isov v lates were confirmed by PCR. 18 21 and HIV seroprevalence estimates from antenatal clinic surveys. 22, 23 We used c²vtest to analyse trends in the proporv v tion of antimicrobial resistant isolates over the five periods and managed and analysed data using Epi Info software, version 6.04d. 24 
Findings
In our study, 920 cases of invasive H. influenzae disease were reported to the surveillance system from July 1999
to June 2004 for all ages; 847 (92%) provided the patient's age. Of the 920 isolates, 712 (77%) were recovered for serotyping and antimicrobial susv v ceptibility testing. With the increased number of surveillance audits through the period, we identified an increasing number of laboratoryvconfirmed cases retrospectively for which no isolates were available. Cases with isolates therefore decreased from 84% during 1999-2000 to 74% during 2003-04, with a signifiv v cant downward trend over the fivevyear period (P = 0.02). Of the 712 viable isolates, 300 (42%) were serotype b (109, 61, 43, 44 and 43, respectively, for the five periods), 104 (15%) were other capsular types and 308 (43%) were unencapsulated H. influenzae.
Among cases for which the patient's age was known, 218 (78%) of 279 Hib isolates and 225 (61%) of 370 other H. influenzae isolates were among children less than five years old (Table 1) . Of Hib cases aged five years and above, 16 (6%) occurred among those aged 5-9 years, 5 (2%) among those aged 10-14 years and 40 (14%) among adults aged 15 years or more. We found that reported cases of invasive disease among children less than five years old caused by Hib decreased substantially during the fivevyear period, while those caused by H. influenzae other than Hib and S. pneumoniae increased to more than twofold (Table 1) . Among children less than five years old with invasive Hib disease, 60% (130 cases) occurred among those below one year (Table 2) , 13% (29) among those aged 12-17 months and 27% (59) among those aged 18 months or more. We noted no significant change in the median age (9 months) of Hib cases among children less than five years old (P = 0.162) durv v ing the entire study period. We found positive cultures from cerebrospinal fluid specimens (with or without other speciv v mens) for over half of these cases (113, 52%), from blood specimens for 104, and from a pleural fluid specimen for one case. We found no reported cases of epiglottitis.
Our analyses revealed that Hib cases decreased by 65% among children less than one year old (55 cases in 1999-2000 to 19 in 2003-04) ( Table 3 ). In Gauteng, Hib cases decreased from 20 to 10, and in the Western Cape from 12 to 2, during the same time period. In Gauteng and Western Cape, rates of reported Hib disease among children below one year decreased by 57% (13.1 (Table 3) . We also found a 79% decrease (from 34 to 7 cases) in national recording of inv v vasive disease among children 1-4 years of age (Table 3 ). The decrease in this age group was also evident in Gauteng and Western Cape (13 to 5 cases and 16 to 1 case, respectively). Our analyses of anv v tenatal HIV seroprevalence rates among pregnant women showed that rates durv v ing 2000-04 increased in Gauteng (from 29% to 33%) and Western Cape (from 9% to 15%) ( Table 3) .
We found that all ampicillinvresistant Hib isolates produced bvlactamase. Alv v though the number of Hib cases dev v creased during the final surveillance year, isolates of Hib were more likely to be amv v picillin resistant (8 (31%) of 26 cases in Includes serotypes a (n = 10), c (n = 6), d (n = 5), e (n = 3) and f (n = 39). 
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A von Gottberg et al. Among four cases who had received one or more Hib vaccine dose and were of known HIVvstatus, three (75%) were HIVvinfected. Clinical outcomes were reported for 29 cases since January 2003, five (17%) of whom died. We observed that nationally over the five years, the median age for nontypable disease (n = 162) and disease due to serotypes other than serotype b (n = 63) among children less than five years old did not change (median age 10 months for both groups). During the period of enhanced surveillance, children with nontypable disease were more likely to be HIVvpositive (32 of 34, 94%) than those with Hib disease (10 of 14, 71%), P = 0.051. All children who had serov v types other than b (12 of 12) were HIV positive.
Discussion
In South Africa, a national laboratoryv based surveillance for invasive Hib disv v ease demonstrated a significant decrease in cases of invasive disease following the introduction of Hib conjugate vaccine into the routine child immunization schedule. While surveillance data did not provide an accurate estimate of the true burden of Hib disease due to limitations of the reporting system, the demonstration of vaccine impact at the national level is important given the decision to provide this relatively expensive vaccine for all South African children. The cost benefits of administerv v ing this vaccine to a 1992 Cape Town birth cohort (n = 46 537) was between US$ 0.8 million and US$ 1.2 million. 25 Our findings are especially important given the high prevalence of HIV in the country.
Although the laboratory reporting system in South Africa may underesv v timate the incidence of Hib disease among children less than five years old, we believe the decrease in Hib disease is a minimum estimate of the full impact of the vaccine in South Africa. Populav v tionvbased studies conducted in Soweto (Gauteng province) in 1997-98 and Cape Town (Western Cape province) in 1991-92 (before the introduction of Hib vaccine) identified annual incidences of invasive Hib disease of approximately 170 cases per 100 000 children below one year.
14,16 These rates were much higher than those detected by our surv v veillance in these two provinces during July 1999-June 2000 -13.1 and 14.6 cases per 100 000 children below one year. In Gauteng, the vaccine had been administered to Soweto children since 1998, and since our surveillance system was established at the time of vaccine introduction (i.e. July 1999) the initial rates of Hib disease are likely to reflect some impact of the immunization. Morev v over, the previmmunization studies were performed at academic hospitals where specimens are routinely collected for diagnostic purposes and laboratories are wellvequipped. We have seen improvev v ments in case ascertainment throughout the country reflected in the increase in isolates of nontype b H. influenzae and S. pneumoniae. In addition, shortages of vaccine were reported during the first years. Thus, we believe that data from the national surveillance are likely to underestimate the impact of Hib vacv v cine and that the 65% decrease in cases among children below one year during the study period should be interpreted as a minimum estimate. 3, 26 In South Africa, national estimates suggest that 8% of 1.1 million children born in 2002 were infected with HIV at birth or through breastfeeding durv v ing their first year of life. 27 Our analysis revealed that the decrease in Hib disease was lower in Gauteng, where HIV serov v prevalence rates were more than twice that in Western Cape. HIV infection was very common among Hib cases at sentinel sites. Lower vaccine effectivev v ness and increased susceptibility to Hib disease among HIVvinfected children may contribute to the persistent low rates of Hib disease in South Africa. 13, 14 Further studies are needed to deterv v mine the relative importance of these two factors. With antiretroviral therapy decreasing mortality and progression to AIDS among infants, 28 and its implev v mentation in Africa showing promising 
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results, 28, 29 it will become more common in paediatric care in South Africa. 30 Thus, monitoring of Hib disease may influence decisions to include additional doses of Hib and other vaccines for HIVvinfected children. 31 We observed an increase in reported cases of nonvHib disease possibly due to improved quality of surveillance, which is supported by the increase in reported pneumococcal disease over the same time period. These diseases may howv v ever also be increasing due to increases in the number of persons living with HIV infection. Data from a small numv v ber of cases from sentinel sites showed that HIV infection was more common among paediatric cases of H. influenzae due to nontypable strains than among cases of Hib. Another explanation may be replacement disease, although it has not been significant in other parts of the world, 32, 33 HIVvcoinfection may conv v tribute to other strains filling the niche previously occupied by Hib. Our data do not allow us to distinguish between the relative contributions of these factors to the observed increase.
The reported coverage with the three doses of Hib vaccine in South Africa was less than that described in developed countries, 26, 34 although several limitations with regard to both numerav v tor data and population denominators hamper accurate coverage estimates. 20, 21 We were unable to obtain sufficient data to determine the true incidence of vaccine failures. Failure after complete vaccination among children 14 weeks old or above was recorded for only one child. We believe that obtaining betv v ter data on vaccination histories will be necessary to determine the role of vaccine failure among infants presentv v ing with Hib disease. [35] [36] [37] South Africa uses an accelerated schedule for Hib vaccine at six, 10 and 14 weeks without a booster dose, 15 which might increase disease prevalence among older children due to waning immunity. 35, 38 In the last year of surveillance (2003-04) however, only seven of 26 cases of Hib disease (for whom age was recorded) occurred after the age at which a booster may be given (i.e. children more than one year old).
We believe that the use of national surveillance data has several important limitations. The true burden of potenv v tially preventable Hib disease may be significantly higher than that observed by culturevconfirmed disease alone.
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We included calculated rates of Hib disv v ease only for cases where viable isolates could be confirmed as type b and for which the age of the patient was known. We did not adjust for the increase in the number of reporting laboratories, or the impact of enhancements made to the surveillance system in 2003, both of which likely increased the number of Hib cases identified. The low number of cases from many provinces may be due to several factors, including low acv v cessibility to health care in rural areas, reduced numbers of blood cultures being taken per patients admitted, 39 smaller rural laboratories not having resources for diagnosis unless as part of studies 40 and underreporting of diagnosed cases by the laboratory to the surveillance unit. Although laboratoryvconfirmed Hib cases are notifiable to the Department of Health in South Africa since 1999, notification remains uncommon and no cases were identified through the national reporting system during our fivevyear study period.
Conclusion
The inclusion of the Hib conjugate vacv v cine in the child immunization schedv v ule is justified in the face of the HIV epidemic which affects a large number of newborns. Increasing antibiotic resisv v tance among Hib isolates in our popuv v lation 12, 41 is an additional justification for vaccine introduction. In the future, better information about underlying conditions and vaccine status together with a carefully planned casevcontrol study will assist decisionvmakers and public health experts Competing interests: none declared. 
